112559-91-8
112559-91-8 結(jié)構(gòu)式
基本信息
伊曲康唑雜質(zhì)1
伊曲康唑代謝物
伊曲康唑2-羥基代謝物
羥基伊曲康唑(伊曲康唑代謝物)
HYDROXY ITRACONAZOLE
Itraconazole Impurity 1
Itraconazole 2-Hydroxy Metabolite
Itraconazole metabolite Hydroxy Itraconazole
4-[4-[4-[4-[[2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylMethyl)-1,3-dioxolan-4-yl]Methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(2-hydroxy-1-Methylpropyl)-
3H-1,2,4-Triazol-3-one, 4-4-4-4-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxyphenyl-1-piperazinylphenyl-2,4-dihydro-2-(2-hydroxy-1-methylpropyl)-
4-[4-[4-[4-[[2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(2-hydroxy-1-methylpropyl)-3H-1,2,4-triazol-3-one
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
Acute Tox. 3 Inhalation
Acute Tox. 3 Oral
Flam. Liq. 2
STOT SE 1
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2025/12/22 | HY-12772 | 羥基伊曲康唑(伊曲康唑代謝物) Hydroxy Itraconazole | 112559-91-8 | 1mg | 1900元 |
| 2024/08/19 | HY-12772 | 羥基伊曲康唑(伊曲康唑代謝物) Hydroxy Itraconazole | 112559-91-8 | 5mg | 7500元 |
| 2023/10/26 | HY-12772 | 羥基伊曲康唑(伊曲康唑代謝物) Hydroxy Itraconazole | 112559-91-8 | 10mg | 12000元 |
常見問題列表
Antifungal
Hydroxy Itraconazole (Itraconazole metabolite Hydroxy Itraconazole; R-63373) is an active metabolite of Itraconazole (ITZ). Although Hydroxy Itraconazole is also reported to have antifungal activity in vitro, its pharmacokinetics in humans has been studied less than that of ITZ. ITZ and Hydroxy Itraconazole have a triazole ring and inhibit CYP3A. Their half-lives can be extended by 26-60% with repeated administration compared to single administration.
The plasma concentration of Hydroxy Itraconazole is weakly dependent on the dose of ITZ, most likely because the process that forms Hydroxy Itraconazole is saturated. Serum albumin and GFR may alter the pharmacokinetics of ITZ and Hydroxy Itraconazole. Antifungal activity should be discussed while taking into account not only the plasma concentration of ITZ but also that of Hydroxy Itraconazole. However, the pharmacokinetics of Hydroxy Itraconazole is similar to that of ITZ in immunocompromised patients taking an oral solution of ITZ. Since the plasma concentrations of ITZ and Hydroxy Itraconazole are closely correlated, determining the plasma concentration of either should be sufficient from a clinical point of view.